Indication

Trimethoprim toxicity

Trimethoprim toxicity is an adverse drug reaction or overdose state caused by exposure to trimethoprim, a dihydrofolate reductase inhibitor used alone or combined with sulfamethoxazole. Read more about Trimethoprim toxicity

45 drugs 36 manufacturers

Advertisement

Drugs that treat it

Common Trimethoprim toxicity therapies.

Showing 37–45 of 45 drugs

LEUCOVORIN CALCIUM

FOLIC ACID·FOLIC ACID DEFICIENT MEGALOBLASTIC ANEMIA·+7
MEITHEAL PHARMA

LEUCOVORIN CALCIUM

FOLIC ACID·FOLIC ACID DEFICIENT MEGALOBLASTIC ANEMIA·+7
WEST-WARD/HI-NO

LEUCOVORIN CALCIUM

FOLIC ACID·FOLIC ACID DEFICIENT MEGALOBLASTIC ANEMIA·+7
GLENMARK PHARMA

LEUCOVORIN CALCIUM

FOLIC ACID·FOLIC ACID DEFICIENT MEGALOBLASTIC ANEMIA·+7
Hikma Pharmaceuticals USA
Filter & compare in the drug finder →Opens the drug finder with Trimethoprim toxicity preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Trimethoprim toxicity.

Trimethoprim toxicity is an adverse drug reaction or overdose state caused by exposure to trimethoprim, a dihydrofolate reductase inhibitor used alone or combined with sulfamethoxazole.

It predominantly affects the renal, metabolic, and hematologic systems, particularly in older adults, individuals with pre-existing renal impairment, or those receiving high doses.

Pathophysiologically, trimethoprim blocks epithelial sodium channels in the distal nephron, inducing hyperkalemia and renal tubular acidosis, while competitively inhibiting tubular creatinine secretion to produce an isolated elevation in serum creatinine.

Chronic overexposure or folate deficiency can also impair host DNA synthesis, leading to hematologic toxicities such as megaloblastic anemia, leukopenia, and thrombocytopenia.

Personalize your experience

Follow Trimethoprim toxicity and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it